The ORZEYFUL oveporexton launch reached patients in Japan and China on the same announcement. On 15 October 2026 Takeda said ORZEYFUL (oveporexton) is available in both countries for narcolepsy type 1. Narcolepsy type 1 is a chronic neurological disease. Oveporexton is an oral medicine that stimulates the orexin receptor 2. Orexin is a brain signal that helps control wakefulness. Takeda calls this the first orexin receptor 2 agonist to reach patients.
The US launch is a separate step. Takeda says it will follow next month, after the Drug Enforcement Administration finishes a controlled-substance scheduling decision. Takeda's announcement does not rank Japan and China by market size.
Approvals
Takeda's releases give the dates.
- 22 July 2026: China's National Medical Products Administration, the NMPA, approved ORZEYFUL for narcolepsy type 1 in adolescents aged 16 and older and in adults. Takeda China thanked the regulator for an accelerated review.
- 5 August 2026: the US Food and Drug Administration, the FDA, approved it for adults. The FDA had given it Breakthrough Therapy designation and Priority Review.
- 24 August 2026: Japan's Ministry of Health, Labour and Welfare, the MHLW, approved it for adults. Takeda called this the third approval worldwide.
- 15 October 2026: Takeda announced availability in Japan and China.
The FDA says the medicine will be lawful to market in the United States once the scheduling decision is issued.
The labels are not the same. Takeda says China covers adolescents from age 16 and adults. It says the US and Japan labels cover adults. Takeda says the disease usually develops between the ages of 10 and 20. That sentence is about the usual age of onset. It is not a patient count.
A China study can include clinicians who see patients from age 16. A Japan or US study, on these labels, cannot treat that age group as in scope. Regional slides should follow each label.
How it works
The FDA describes narcolepsy type 1 as the result of losing orexin. The symptoms it lists are excessive daytime sleepiness, cataplexy, sleep paralysis, hallucinations around sleep and broken night-time sleep. Cataplexy is sudden muscle weakness, often triggered by strong emotion. The FDA estimates that narcolepsy type 1 affects about 1 in 2,000 people in the United States. That estimate is for the United States.
ORZEYFUL is an oral tablet. It selectively stimulates the orexin 2 receptor. The FDA calls it the first medicine approved for narcolepsy type 1 as a complete disorder, and the first that directly targets the loss of orexin signalling. Older treatment, the FDA says, targeted individual symptoms.
The approvals rest on two phase 3 studies, FirstLight and RadiantLight. Takeda says both were placebo-controlled over 12 weeks, ran in 19 countries, and finished enrolment within six months. Takeda says FirstLight enrolled 168 participants and RadiantLight enrolled 105. The FDA describes randomised, double-blind studies enrolling 273 adults in total. Those figures are study enrolments. They are not a count of people already treated.
Takeda says both studies showed statistically significant improvements over placebo in wakefulness, sleepiness, cataplexy, disease severity and quality of life, with p-values below 0.001 across doses. Takeda lists the most common side effects as insomnia, urinary urgency, urinary frequency and excessive saliva. The FDA says the medicine should not be used with strong CYP3A inhibitors. A CYP3A inhibitor is a drug that blocks a liver enzyme which clears many medicines.
Japan dose
The dose in this section is the Japan dose. It is not copied onto China. The sources used here do not state a China dose.
Takeda's Japan product overview gives the usual adult dose as 1 mg twice daily. The first dose is on waking. The second is three to five hours later. The dose can rise to 2 mg twice daily only when it is well tolerated and the effect is not enough. Tablets come in 0.5 mg, 1 mg and 2 mg.
Japan price
In Japan, a new medicine is listed on the National Health Insurance price list, the NHI list, before public insurance pays for it. The Central Social Insurance Medical Council, Chuikyo, approved the listing at its meeting on 7 October 2026. The MHLW new drug list sets the listing date as 14 October 2026.
The MHLW file lists the price per tablet as JPY 22,773.30 for 0.5 mg, JPY 22,792.50 for 1 mg and JPY 22,838.80 for 2 mg. The three strengths are close. A move from 1 mg to 2 mg twice daily barely changes the cost per day on this list. These are Japan list prices. They are not a China price.
The file uses the cost accounting method. It does not use a comparison with a similar medicine. The file says no listed product has narcolepsy type 1 as its indication. Medicines listed for narcolepsy more broadly have been on the list for more than ten years, so they are not suitable comparators. Products that act on orexin receptors and are already listed are antagonists used for insomnia. The pricing body concluded there was no most-similar medicine.
The file records three premiums.
- A usefulness premium (I) at 40%. The file cites a new mechanism, no new-mechanism listing in this disease for about 19 years and 7 months, and improvement on important secondary endpoints against placebo.
- A marketability premium (I) at 10%, because the medicine is an orphan drug in Japan.
- A Sakigake premium at 10%, because of the Sakigake review scheme. The file sets the rate at 10% because several other countries had approved it before Japan. Sakigake is a Japanese priority-review designation.
The addition coefficient is 0. The file shows the same prices before and after the premiums. The premiums were granted. They did not raise the listed price. There was no foreign average price adjustment. The file says no foreign price existed. It names China, in July 2026, as the first country of approval.
The file says the medicine qualifies for the system that maintains prices for innovative new drugs, mainly because of the orphan designation. It lists the medicine for cost-effectiveness evaluation, category H2. The price can change after that evaluation. H2 is a Japanese cost-effectiveness category. It is not a China reimbursement decision.
The file includes Takeda's own forecast. Takeda forecast 423 patients and sales of JPY 7.04 billion in the tenth year, at peak. That is a company forecast of treated patients in Japan. It is not a disease count.
China
Takeda's China approval release says narcolepsy affects an estimated 700,000 people in China. It says narcolepsy type 1 makes up about 75 to 80 percent of cases. These are company figures. The percentage is a share of narcolepsy cases in the company's sentence. It is not a calculated patient total.
Takeda also cites an average diagnostic delay of more than 10 years for narcolepsy. It links the delay to limited awareness and complex symptoms. That delay is a company citation. It is not a count of undiagnosed people.
Japan's 423 is a treated-patient forecast at year 10. China's 700,000 is an estimate of people with narcolepsy. They measure different things. Neither figure is a launch volume.
Takeda's releases used here do not say how ORZEYFUL is reimbursed in China, and they do not state the China dose. The Japan dose stays in the Japan section.
What to ask
Narcolepsy type 1 is diagnosed in sleep centres and in specialist neurology and psychiatry. Japan's forecast of a few hundred treated patients at peak points to a short account list. The China releases used here do not name the hospitals. A team can ask which centres diagnose the disease, who adds a medicine to the hospital list, and how patients are followed. Those are questions for a study. They are not a hospital list.
Takeda cites a diagnostic delay of more than 10 years. A study can ask referring physicians where patients are lost. It should not turn the delay into a national untreated count.
For a first-in-class medicine, prescribers have no habit to copy. Ask which patients they would treat first. Ask whether they would replace current treatment, add to it, or reduce it. In Japan, ask how often they expect to use 2 mg twice daily. That dose question stays in Japan. Ask how they would manage insomnia and urinary symptoms. Ask which sign of success they will use, and over what time.
The same core questions can run in Japan and in China if each instrument follows that country's label. For study design, see physician surveys in healthcare.
US timing
In its August release, Takeda said the DEA classification was expected within 90 days. It said ORZEYFUL would then be sold through a specialty pharmacy in the United States. The Asian availability announcement came first. Takeda announced availability in Japan and China while the US launch waits on scheduling.
Later products
Takeda describes ORZEYFUL as the lead medicine in its orexin franchise. The company is also developing TAK-360 for narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia, and another orexin agonist, TAK-495. Idiopathic hypersomnia is excessive sleepiness without another identified cause. Later products are a company pipeline. They are not approved uses of ORZEYFUL.
A centre that adopts the first medicine may matter again if a later product reaches it. That is a planning reason to learn how the centre diagnoses and refers. It is not a forecast of the later products.
Planning notes
Three approvals inside about five weeks were not three launches on the approval dates. Japan needed the NHI listing. China moved on its own timetable. The United States still needed scheduling.
Japan's new drug file states the pricing method, the premiums, the comparator decision and the company's forecast. A team launching another new medicine in Japan can read the closest file in its own area. This file does not set a China price.
Category H2 means a later evaluation can change the Japanese price. Real-world outcomes are a Japan evidence question.
China's label includes patients from 16 years. Japan and the US labels used here do not. Medical education should follow the label in each country. The Japan dose should not appear on a China slide.
Frequently asked questions
What is ORZEYFUL (oveporexton)?
An oral orexin receptor 2 agonist from Takeda for narcolepsy type 1. Orexin is a brain signal that helps control wakefulness. The FDA calls it the first medicine to directly target the loss of orexin signalling that causes the disease.
Where is ORZEYFUL available?
Takeda announced availability in Japan and China on 15 October 2026. It says the US launch will follow next month, after DEA scheduling. The announcement does not rank the two markets by size.
Who can be treated?
Takeda says the China approval covers adolescents aged 16 and older and adults with narcolepsy type 1. It says the US and Japan approvals cover adults. The China release used here does not state a dose.
What is the price in Japan?
The MHLW new drug list sets JPY 22,773.30 for 0.5 mg, JPY 22,792.50 for 1 mg and JPY 22,838.80 for 2 mg per tablet, listed from 14 October 2026. Those prices are for Japan.
How was the Japanese price set?
The MHLW file uses the cost accounting method, because no suitable comparator existed. Premiums were granted, but the addition coefficient was 0, and the medicine is subject to cost-effectiveness evaluation (H2).
What should APAC teams research first?
Which sleep centres diagnose narcolepsy type 1, how patients are referred, and how specialists in each country will select patients. Ask the Japan dose only in Japan. The China disease estimate is not a calculated patient total.
Plan your APAC launch research with BioNixus
BioNixus has run primary market research since 2012, with physician and account fieldwork across 48 countries, including Japan and China. See healthcare market research in Japan and healthcare market research in China.
If you are preparing a first-in-class launch in Japan or China, contact our team.
Based on public filings and company announcements. This is not clinical guidance and not a recommendation to prescribe.
Sources
All accessed 17 October 2026.
- Takeda, "Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China", 15 October 2026: https://www.takeda.com/newsroom/newsreleases/2026/oveporexton-launches-simultaneously-in-japan-and-china/
- Takeda China, "ORZEYFUL Approved in China for Narcolepsy Type 1", 22 July 2026: https://www.takeda.com/newsroom/newsreleases/2026/orzeyful-approved-china-narcolepsy/
- Takeda, "FDA Approves ORZEYFUL for Adults With Narcolepsy Type 1", 5 August 2026: https://www.takeda.com/newsroom/newsreleases/2026/orzeyful-approved-narcolepsy/
- US FDA, "FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms", 5 August 2026: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms
- Takeda, "ORZEYFUL Approved in Japan to Treat Narcolepsy Type 1", 24 August 2026: https://www.takeda.com/newsroom/newsreleases/2026/orzeyful-approved-japan-narcolepsy/
- MHLW, 新医薬品一覧表 (new drug list, listing 14 October 2026), Chuikyo 7 October 2026: https://www.mhlw.go.jp/content/10808000/001756860.pdf
- BioNixus, About page: https://www.bionixus.com/about





